JP2009525046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525046A5 JP2009525046A5 JP2008553336A JP2008553336A JP2009525046A5 JP 2009525046 A5 JP2009525046 A5 JP 2009525046A5 JP 2008553336 A JP2008553336 A JP 2008553336A JP 2008553336 A JP2008553336 A JP 2008553336A JP 2009525046 A5 JP2009525046 A5 JP 2009525046A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- kinase
- synuclein
- activity
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 11
- 101710183243 Serine/threonine-protein kinase PLK2 Proteins 0.000 claims 10
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 claims 10
- 102000003802 alpha-Synuclein Human genes 0.000 claims 8
- 108090000185 alpha-Synuclein Proteins 0.000 claims 8
- 208000009829 Lewy Body Disease Diseases 0.000 claims 6
- 201000002832 Lewy body dementia Diseases 0.000 claims 6
- 108091000080 Phosphotransferase Proteins 0.000 claims 6
- 102000020233 phosphotransferase Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 238000010171 animal model Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102000019355 Synuclein Human genes 0.000 claims 2
- 108050006783 Synuclein Proteins 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 101710185494 Zinc finger protein Proteins 0.000 claims 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 102200036624 rs104893875 Human genes 0.000 claims 2
- 102200036626 rs104893877 Human genes 0.000 claims 2
- 102200036620 rs104893878 Human genes 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000057269 human PLK2 Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011820 transgenic animal model Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76400006P | 2006-01-31 | 2006-01-31 | |
| PCT/US2007/002685 WO2007089862A2 (en) | 2006-01-31 | 2007-01-30 | Alpha-synuclein kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525046A JP2009525046A (ja) | 2009-07-09 |
| JP2009525046A5 true JP2009525046A5 (enExample) | 2010-04-08 |
Family
ID=38328036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553336A Pending JP2009525046A (ja) | 2006-01-31 | 2007-01-30 | アルファ−シヌクレインキナーゼ |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7553639B2 (enExample) |
| EP (1) | EP1989330A4 (enExample) |
| JP (1) | JP2009525046A (enExample) |
| CA (1) | CA2641219A1 (enExample) |
| WO (1) | WO2007089862A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007089862A2 (en) | 2006-01-31 | 2007-08-09 | Elan Pharmaceuticals, Inc. | Alpha-synuclein kinase |
| WO2009103010A2 (en) * | 2008-02-13 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Alpha-synuclein kinase |
| JP5747414B2 (ja) * | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| US20100317646A1 (en) * | 2009-03-19 | 2010-12-16 | Medical Research Council Technology | Compounds |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| US9458463B2 (en) | 2010-09-03 | 2016-10-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for treatment of diabetes by a small molecule inhibitor for GRK5 |
| EP2426202A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Kinases as targets for anti-diabetic therapy |
| WO2014132249A1 (en) * | 2013-02-26 | 2014-09-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for the assay of synucleins |
| WO2018057782A1 (en) * | 2016-09-23 | 2018-03-29 | University Of Utah Research Foundation | Methods of preventing stem cell differentiation using a pask inhibitor |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| US20210041461A1 (en) | 2018-03-14 | 2021-02-11 | Yissum Research Developmen Company Of The Hebrew University Of Jerusalem Ltd | Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies |
| FI4172199T3 (fi) | 2020-06-26 | 2025-08-12 | Bioarctic Ab | Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet |
| CN114601928B (zh) * | 2022-04-02 | 2023-03-17 | 首都医科大学 | 一种钙超载介导神经元死亡的标志物及应用 |
| CN115569202A (zh) * | 2022-10-19 | 2023-01-06 | 苏州捷乐思生物科技有限公司 | 一种帕金森综合征动物模型、药物筛选方法及治疗药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001060794A2 (en) * | 2000-02-18 | 2001-08-23 | The Regents Of The University Of California | Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| CN1440420A (zh) * | 2000-07-07 | 2003-09-03 | 万能药制药公司 | 预防神经组织损伤和治疗α－共核蛋白疾病的方法 |
| RS95404A (sr) | 2002-05-03 | 2006-10-27 | Schering Aktiengesellschaft | Tiazolidinoni i njihova primena kao inhibitora polo like kinaze |
| US20060211624A1 (en) * | 2003-02-02 | 2006-09-21 | Goverment of the US, as Represented by | Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE10351744A1 (de) | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7566548B2 (en) | 2004-08-13 | 2009-07-28 | University Of Massachusetts | Methods for identifying therapeutic agents and for treating disease |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1827473A4 (en) | 2004-12-01 | 2009-08-19 | Whitehead Biomedical Inst | MODULATOR OF ALPHA SYNNUCLEINE TOXICITY |
| JP2008524139A (ja) * | 2004-12-15 | 2008-07-10 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | メタ置換チアゾリノン類、それらの製造及び医薬としての使用 |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US20070010565A1 (en) | 2005-04-25 | 2007-01-11 | Olaf Prien | New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |
| DE102005020104A1 (de) | 2005-04-25 | 2006-10-26 | Schering Ag | Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel |
| EP1888095A4 (en) * | 2005-05-13 | 2009-08-26 | Whitehead Biomedical Inst | MODULATORS OF ALPHA-SYNUCLEIN INDUCED TOXICITY |
| US8017781B2 (en) | 2005-11-15 | 2011-09-13 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| CN101336244B (zh) | 2005-12-08 | 2011-11-30 | 雅培制药有限公司 | 用作蛋白激酶抑制剂的9元杂二环化合物 |
| TW201307354A (zh) | 2005-12-29 | 2013-02-16 | Abbott Lab | 蛋白質激酶抑制劑 |
| WO2007089862A2 (en) | 2006-01-31 | 2007-08-09 | Elan Pharmaceuticals, Inc. | Alpha-synuclein kinase |
| WO2009103010A2 (en) | 2008-02-13 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Alpha-synuclein kinase |
-
2007
- 2007-01-30 WO PCT/US2007/002685 patent/WO2007089862A2/en not_active Ceased
- 2007-01-30 EP EP07762749A patent/EP1989330A4/en not_active Withdrawn
- 2007-01-30 US US11/669,093 patent/US7553639B2/en not_active Expired - Fee Related
- 2007-01-30 JP JP2008553336A patent/JP2009525046A/ja active Pending
- 2007-01-30 CA CA002641219A patent/CA2641219A1/en not_active Abandoned
-
2008
- 2008-02-13 US US12/030,849 patent/US20080300206A1/en not_active Abandoned
-
2010
- 2010-02-08 US US12/702,201 patent/US8148089B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525046A5 (enExample) | ||
| Seifert et al. | The influence of fundamental traits on mechanisms controlling appendage regeneration | |
| Von Koch et al. | Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice | |
| Bahi et al. | Dopamine transporter (DAT) knockdown in the nucleus accumbens improves anxiety-and depression-related behaviors in adult mice | |
| Koprich et al. | Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease | |
| Sennvik et al. | Tau‐4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice | |
| JP2003517580A5 (enExample) | ||
| EP3436476A1 (en) | Anti-ryk antibodies and methods of using the same | |
| CN114286710A (zh) | 治疗亨廷顿病的方法和材料 | |
| CN110628814B (zh) | 基于基因编辑技术增加smn蛋白表达的方法及其在sma治疗中的应用 | |
| Rahman et al. | Early postnatal lead exposure induces tau phosphorylation in the brain of young rats | |
| Libertini | The role of telomere-telomerase system in age-related fitness decline, a tameable process | |
| McHenry et al. | Overexpression of fra-2 in transgenic mice perturbs normal eye development | |
| CN101942463B (zh) | 一种建立急性多型性卟啉病转基因小鼠模型的方法 | |
| Schmouth et al. | Non-coding-regulatory regions of human brain genes delineated by bacterial artificial chromosome knock-in mice | |
| CN108719145B (zh) | 一种用于筛选治疗帕金森病药物的斑马鱼模型构建方法 | |
| CN118421703B (zh) | 一种自发出现情绪异常波动的非人哺乳动物模型的构建方法及其用途 | |
| WO2006026478A3 (en) | Compositions and methods for improving heart function | |
| KR100734815B1 (ko) | Ｈｔａｕ24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법 | |
| Götz et al. | Human tau transgenic mice: towards an animal model for neuro-and glialfibrillary lesion formation | |
| KR100635865B1 (ko) | Ａｐｐ/ｃ-105 돌연변이 유전자를 발현하는 형질전환 치매마우스 | |
| Patil | Effects of Ablation of Fibroblasts on the Structure and Function of Salivary Gland | |
| CN110564771B (zh) | 脑钙化病模型的制备方法 | |
| KR101444297B1 (ko) | Ｃｙｐ４ｆ１６ 유전자가 넉다운된 형질전환마우스 및 그 제조방법 | |
| US20130047273A1 (en) | Genetically altered animal specimen and related methods |